CINECA IRIS Institutional Research Information System

FERRARI, SILVIA MARTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.300
AS - Asia 6.744
EU - Europa 5.427
SA - Sud America 1.389
AF - Africa 217
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 7
Totale 30.102
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.904
IT - Italia 2.280
SG - Singapore 2.084
CN - Cina 1.927
HK - Hong Kong 1.309
BR - Brasile 1.181
SE - Svezia 837
BG - Bulgaria 523
VN - Vietnam 523
DE - Germania 438
CA - Canada 299
RU - Federazione Russa 294
GB - Regno Unito 277
TR - Turchia 272
FI - Finlandia 218
IN - India 137
FR - Francia 116
UA - Ucraina 112
AR - Argentina 79
IQ - Iraq 79
NL - Olanda 78
BD - Bangladesh 73
CI - Costa d'Avorio 60
JP - Giappone 53
KR - Corea 48
MX - Messico 47
PL - Polonia 47
AT - Austria 38
EC - Ecuador 34
ES - Italia 30
ZA - Sudafrica 30
ID - Indonesia 28
BE - Belgio 26
CO - Colombia 26
SA - Arabia Saudita 26
SN - Senegal 25
NG - Nigeria 23
PK - Pakistan 23
MA - Marocco 22
PY - Paraguay 22
CZ - Repubblica Ceca 20
CH - Svizzera 19
VE - Venezuela 19
UZ - Uzbekistan 17
AU - Australia 15
IE - Irlanda 15
IR - Iran 15
JO - Giordania 15
TN - Tunisia 14
AE - Emirati Arabi Uniti 12
LT - Lituania 12
KE - Kenya 11
NP - Nepal 11
PH - Filippine 11
EG - Egitto 9
PE - Perù 9
RO - Romania 9
UY - Uruguay 9
DO - Repubblica Dominicana 8
IL - Israele 8
JM - Giamaica 8
MY - Malesia 7
OM - Oman 7
AL - Albania 6
BH - Bahrain 6
BJ - Benin 6
DZ - Algeria 6
GT - Guatemala 6
HU - Ungheria 6
KZ - Kazakistan 6
BY - Bielorussia 5
CL - Cile 5
LB - Libano 5
PS - Palestinian Territory 5
TT - Trinidad e Tobago 5
AM - Armenia 4
AZ - Azerbaigian 4
CR - Costa Rica 4
EU - Europa 4
GE - Georgia 4
GR - Grecia 4
HN - Honduras 4
NI - Nicaragua 4
TW - Taiwan 4
BN - Brunei Darussalam 3
BO - Bolivia 3
CU - Cuba 3
DK - Danimarca 3
KW - Kuwait 3
PA - Panama 3
PT - Portogallo 3
QA - Qatar 3
RS - Serbia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
ET - Etiopia 2
GA - Gabon 2
GY - Guiana 2
HR - Croazia 2
KG - Kirghizistan 2
Totale 30.073
Salva come PNG Salva come JPEG
Città #
Fairfield 1.867
Ashburn 1.755
Woodbridge 1.525
Hong Kong 1.298
Singapore 1.121
Houston 1.060
Dallas 1.026
Santa Clara 849
Ann Arbor 840
Seattle 817
Chandler 796
Serra 790
Cambridge 684
Wilmington 664
Shanghai 532
Sofia 522
Milan 464
Beijing 425
New York 338
Boardman 262
Princeton 257
Ottawa 237
Pisa 230
Lawrence 204
Los Angeles 202
Medford 195
Nanjing 145
Dong Ket 139
Izmir 134
Des Moines 129
Munich 118
Jacksonville 112
São Paulo 107
Istanbul 98
Redondo Beach 97
London 95
Florence 87
San Diego 87
Buffalo 86
Ho Chi Minh City 78
Hefei 77
Dearborn 73
Frankfurt am Main 73
Columbus 70
Rome 70
The Dalles 69
Abidjan 60
Boulder 52
Seoul 47
Tokyo 46
Paris 40
San Jose 40
Hanoi 39
Nanchang 39
Redwood City 39
Rio de Janeiro 39
Council Bluffs 37
Kunming 37
Ogden 37
Helsinki 36
Falls Church 35
Fuzhou 35
Turku 35
Chicago 33
Bremen 32
Hebei 32
Shenyang 32
Warsaw 32
Changsha 31
Norwalk 29
Phoenix 29
Belo Horizonte 27
Nuremberg 27
Baghdad 25
Brussels 25
Dakar 25
Rho 23
Dhaka 22
Jiaxing 22
San Francisco 22
Sulaymaniyah 22
Tianjin 22
Washington 22
Brooklyn 21
Guangzhou 21
Pune 21
Amsterdam 20
Lagos 20
Vienna 20
Johannesburg 19
Toronto 19
Brasília 18
Denver 18
Jüchen 18
Curitiba 16
Düsseldorf 16
Massa 16
Tashkent 16
Zhengzhou 16
Amman 15
Totale 22.441
Salva come PNG Salva come JPEG
Nome #
Hepatitis C Virus Infection: Evidence for an Association With Type 2 Diabetes: Response to Skowronski et al. 241
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 228
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 222
Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. 216
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 214
Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. 211
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 211
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 209
Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia 206
Autoimmune thyroid disorders 204
Molecular testing in the diagnosis of differentiated thyroid carcinomas 204
Sorafenib in the treatment of thyroid cancer 203
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 197
Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy 196
Aggressive thyroid cancer: targeted therapy with sorafenib 193
Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts 192
Sunitinib in the treatment of thyroid cancer 192
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors 191
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro 188
Sorafenib and Thyroid Cancer 187
Increased CXCL9 Serum Levels in Hepatitis C-Related Mixed Cryoglobulinemia, with Autoimmune Thyroiditis, Associated with High Levels of CXCL10 183
The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases 183
Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study 182
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone 174
Selective use of vandetanib in the treatment of thyroid cancer 173
Novel therapies for thyroid autoimmune diseases: An update 172
Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ 171
CCL2 is Modulated by Cytokines and PPAR-g in Anaplastic Thyroid Cancer 171
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer 170
Cytokines and HCV-Related Disorders. 169
TSH Normalization in Bariatric Surgery Patients After the Switch from l-Thyroxine in Tablet to an Oral Liquid Formulation 168
Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied 168
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition 168
Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide 166
Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine 165
Thyroid disorders induced by checkpoint inhibitors 165
Cabozantinib in Thyroid Cancer 164
CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes 163
The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients 163
Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study 163
New insight in endocrine-related adverse events associated to immune checkpoint blockade 163
New targeted molecular therapies for dedifferentiated thyroid cancer. 160
RET TKI: Potential Role in Thyroid Cancers 160
Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature 160
Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests 160
Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. 159
Cytokines and HCV-related autoimmune disorders 159
Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection 158
Genotoxicity Evaluation of the Soybean Isoflavone Genistein in Human Papillary Thyroid Cancer Cells. Study of Its Potential Use in Thyroid Cancer Therapy 156
Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy 156
High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C 155
The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): Review of the literature and report of a large series 154
New targeted therapies for anaplastic thyroid cancer. 152
Endocrine Manifestations of HCV-Positive Cryoglobulinemia 151
THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors 151
Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. 150
Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells 150
Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy 150
Graves’ disease: Epidemiology, genetic and environmental risk factors and viruses 150
Incidence of thyroid disorders in systemic sclerosis: results from a longitudinal follow-up 150
Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update 149
Immunomodulation of CXCL10 secretion by hepatitis C virus: Could CXCL10 be a prognostic marker of chronic hepatitis C? 149
β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy 148
DICER1 Syndrome: A Multicenter Surgical Experience and Systematic Review 146
The emerging extrahepatic manifestations oh hepatitis C virus infection in chronic hepatitis and mixed cryoglobulinemia. 146
Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy 146
Novel treatments for anaplastic thyroid carcinoma 146
Age-dependent changes in CXC chemokine ligand 10 serum levels in euthyroid subjects. 145
Vanadium pentoxide induces the secretion of CXCL9 and CXCL10 chemokines in thyroid cells 145
High serum levels of CXCL11 in mixed cryoglobulinemia are associated with increased circulating levels of interferon-γ. 145
Thyroid involvement in hepatitis C - Associated mixed cryoglobulinemia 145
Thyroid uptake of 67Ga-citrate is associated with thyroid autoimmunity and hypothyroidism in patients with sarcoidosis. 144
Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture 143
Interleukin-1β, C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis. 142
Recent advances in precision medicine for the treatment of anaplastic thyroid cancer 142
Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. 141
Hepatitis C virus infection - Evidence for an association with type 2 diabetes 141
Tyrosine Kinase Inhibitors; Therapies for Thyroid Cancer 141
Increased risk of papillary thyroid cancer in systemic sclerosis associated with autoimmune thyroiditis 141
Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study 141
Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis 140
High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. 140
Novel treatment options for anaplastic thyroid cancer 139
The Role of Total Thyroidectomy in the Initial Treatment of Well-differentiated Follicular-cell-derived Thyroid Carcinomas 139
Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. 138
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration 138
CXCL8 and CXCL11 chemokine secretion in dermal fibroblasts is differentially modulated by vanadium pentoxide 138
The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine 138
IFN-γ and TNF-α induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls. 137
Prevalence of hypothyroidism and Graves disease in sarcoidosis 137
Novel Therapies for Thyroid Autoimmune Diseases 137
Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up 137
Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. 136
Myo-inositol in autoimmune thyroiditis, and hypothyroidism 136
Immune and inflammatory cells in thyroid cancer microenvironment 136
Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. 135
CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation 135
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer 135
Systemic sclerosis fibroblasts show specific alterations of interferon-γ and tumor necrosis factor-α-induced modulation of interleukin 6 and chemokine ligand 2. 133
The protective effect of myo-inositol on human thyrocytes 133
Totale 16.233
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.052
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.052
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.211 0 0 0 0 0 60 48 271 105 269 94 364
2021/20222.495 42 116 112 158 412 329 75 163 133 86 166 703
2022/20232.421 361 293 160 194 271 340 46 166 353 11 189 37
2023/20242.112 183 233 257 183 315 385 118 73 35 43 69 218
2024/20257.069 158 267 112 444 702 911 576 397 608 872 728 1.294
2025/20265.043 657 1.003 1.163 738 735 747 0 0 0 0 0 0
Totale 30.977